A Better Newspaper

## Overview Abbott Laboratories is facing ongoing litigation in Illinois alleging that its preterm infant formula contributed to necrotizing enterocolitis (NEC), a serious and potentially fatal intestinal condition in premature babies (Top Class Actions, April 15). ## Latest Verdict An Illinois jury awarded an additional $17 million in damages against Abbott in April 2026, building on prior verdicts in the same litigation wave (Top Class Actions, April 15). The jury found Abbott liable for the alleged contribution of its formula to NEC in premature infants. ## Litigation Context This verdict is part of a developing, multi-plaintiff litigation series rather than a single case. The damages phase is ongoing, indicating further verdicts are likely. The ByHeart Infant Formula MDL Consolidation is a related proceeding in the infant formula litigation space, suggesting the sector as a whole faces sustained legal exposure. ## Legal Significance - **Product liability**: The cases present complex causation questions linking a nutritional product to an intestinal condition in a vulnerable population - **Damages trajectory**: Multiple verdicts with incrementally disclosed totals suggest escalating aggregate liability exposure for Abbott - **Scientific evidence**: NEC causation is scientifically contested, making expert testimony central to outcomes - **Regulatory backdrop**: The FDA's oversight of preterm infant formula formulation is relevant to both liability and any preemption defenses Abbott may assert ## Abbott's Position Abbott's specific litigation defenses and public statements on the verdict have not been fully detailed in available reporting. ## Watch Future developments to track include: additional jury verdicts; any MDL consolidation proceedings; potential settlement negotiations; and FDA regulatory responses to NEC-related claims.